

Pharma Partnering Conference

1 - 2 April 2025, BASEL

VIA Basel, Switzerland

Silver
Sponsors



TILLOTTS PHARMA

WEP
With Every Patient.

Elevate
Partner



Delta4
digital drug discovery & development

Dear Colleague



Welcome to the Pharma Partnering Conference: Driving Innovation Through Strategic Collaborations

In today's rapidly evolving pharmaceutical landscape, partnerships are more critical than ever for driving innovation, accelerating drug development, and improving patient outcomes. The **Pharma Partnering Conference** brings together industry leaders, biotech innovators, and investors to explore the transformative power of collaborations across the value chain. Whether you're a large pharmaceutical company seeking new pipeline opportunities, a biotech startup looking for strategic alliances, or an investor evaluating early-stage ventures, this conference is designed to provide you with the insights and connections you need to succeed.



What will be **DISCUSSED?**



Key Topics:

- 📌 **The Power of Partnerships:** Learn how collaborations across research, clinical development, and manufacturing are shaping the future of pharma.
- 📌 **Deal-Making Strategies:** Discover best practices in structuring and executing deals that maximize value for all parties.
- 📌 **Innovative Technologies:** Explore the role of AI in drug discovery, clinical trial designs, and diagnostics, moving beyond the hype to real-world applications.
- 📌 **Investment Insights:** Gain an investor's perspective on what drives confidence in early-stage biotech companies and how to position your venture for success.
- 📌 **Biotech and Big Pharma Collaborations:** Understand the complexities of deal-making between biotech companies and big pharma, and learn how to navigate these partnerships for mutual benefit.

Join us at the **Pharma Partnering Conference** and be part of the conversations that are shaping the future of the pharmaceutical industry. Don't miss this opportunity to connect, collaborate, and innovate!

Key Features:

- 📌 **Expert-Led Keynotes:** Hear from top industry executives and investors as they share their experiences and strategies for success in pharma partnerships.
- 📌 **Interactive Panel Discussions:** Engage with experts as they dive into the practical challenges and opportunities in deal-making, technology adoption, and partnership management.
- 📌 **Company Showcases:** Discover innovative biotech and pharma companies showcasing their latest developments and partnership opportunities.
- 📌 **Matchmaking Sessions:** Take advantage of dedicated 1-on-1 meetings with potential partners, allowing you to explore new opportunities for collaboration.
- 📌 **Networking Opportunities:** Connect with peers, thought leaders, and potential partners in an environment designed to foster meaningful relationships and collaborations.

Why Attend?

- 📌 **Gain Actionable Insights:** From real-world case studies to strategic advice, you'll leave with practical knowledge that can drive your organization's success.
- 📌 **Discover New Opportunities:** Identify potential partners, collaborators, and investors that can help you accelerate your drug development and commercialization efforts.
- 📌 **Stay Ahead of Industry Trends:** Learn about the latest trends in AI, data-driven decision-making, and investment in the pharma and biotech space.
- 📌 **Expand Your Network:** Forge valuable connections with industry leaders, investors, and innovators, opening the door to new strategic partnerships.

Testimonials



Karen Forsha, Ph.D.
Sr. Manager, Quality Systems
Terumo



„I had the opportunity to offer participants insight on how to positively impact others' well-being and influence organizational outcomes by viewing resilience, grit, and growth mindset as their leadership superpower! The dialogue afterwards was inspiring.“



Gunther Lenz
Vice President Software R&D
Biosciences BD



“Digital Transformation in PPM at the #MedTechSummit! It's always inspiring to connect with fellow professionals who are equally passionate about harnessing digital tools to revolutionize project and portfolio management in healthcare. Let's continue this conversation and keep the ideas flowing!“



Arite Wildau
Director Patient Safety
BIOTRONIK



“Great open dialogue in an expert community. Many valuable presentations, panel discussions and time for networking to share best practices and different views on similar challenges. Warm atmosphere to grow as team over two fabulous days. Also excellently organized and moderated by the WHY SUMMIT TEAM. Happy to join next year as well!“



Sarah Paro
Global QMS Associate
Director



„Last week I had the opportunity to share my experiences and learn from industry experts at Why Summits MedTech Summit. It was an incredible experience!“



Surinder Dhillon
Head of Commercial PMO,
International
Hologic



„I found the sessions were well organized, with an interesting mix of attendees from across the industry. Various key topics were covered, all pertinent to the current MedTech landscape with good discussions on common challenges and sharing of useful lessons, practical applications and future proofing strategies.“



Benjamin Rochette
Vice President, Global Regulatory
Affairs
Coloplast



“I joined the conference in Spring 2023 and really enjoyed it. The program covered several topics of direct relevance to my daily activities, while also giving me perspectives on 'macro trends' of the medical devices industry. Speakers were experts and participants motivated to interact between sessions.“



Renea Olsen
Post-Market Surveillance Manager,
Scientific Affairs
3shape



“The fact that the conference is relatively small generates a very open dialog and it makes it easy to network“



**Susanna Girard, MBA, PMP,
ACP**
Senior R&D Program Manager
J&J MedTech



„Great discussions! It was my pleasure to be a part of it and get to know so many great people working in the industry.“



2025 PPM Summits **Worldwide**



Industry **Pioneers** Attending From



GSK  **Pfizer** *Lilly*  **MERCK**  **Roche** **sanofi** *AstraZeneca* 

 **Bristol Myers Squibb**  **NOVARTIS** **abbvie**  **Boehringer Ingelheim** **Johnson&Johnson**

AMGEN  **VERTEX**  **Genmab**  **GILEAD**  **Takeda**  **novo nordisk**

 **BAYER** **teva**  **Biogen**  **Daiichi-Sankyo** **CSL**  **Otsuka**  **Adaptimmune**

 **Mylan**  **astellas**  **VIATRIS** **SANDOZ** **BIONTECH** **moderna**

Confirmed Speakers:



Ana Paula Tediosi

Head of Expanded Access
Program Strategy

WEP Clinical



Benjamin Fischer

VP Global Alliance & Integration
Management

STADA Group



Charlie Bailey

BD&L Transactions Head,
Global Health, Corporate &
Business Development

Novartis AG



Delphine Demeestere

Director of External Innovation

Lonza



Fadi Eskandar

SVP, Head of External
Ecosystem Collaboration and
Partnership, Innovative Assets

Dr. Reddy's Laboratories



Gabriela M. Visser

Founder & CEO

Q-Pro Laboratories B.V.



Hiro Usuda

Scouting & Transaction Lead,
Business Development

Astellas Pharma



Huseyin Ocak

Global Alliance Management
Lead, Consumer Healthcare

Opella



Isabella Visconti

Founder

**Visconti Alliance
Management**



Jari Kaunisto

Business Development Director

Orion Corporation



Jean-Eric Charoin

Global S&E Lead CVM,
Immunology and Infectious
Diseases, Pharma Partnering

Roche



Kurt Herpel

CEO

Delta4

Confirmed Speakers:



Lev Kogon

VP, Head of Business Development

Nykode Therapeutics



Louise Jopling

Chief Scientific & Innovation Officer

Babraham Research Campus



Luis Correia

Founder & CEO

Basel Biotech Consulting



Michael R Huebner

Director, Country Lead Switzerland, Early Innovation Partnering

Johnson & Johnson



Ragip Ziyal

Head of Corporate Development

Tillotts Pharma



Rainer Strohmenger

Managing Partner

Wellington Partners



Ricardo Gaminha Pacheco

Strategic Partnering, Business Development & Licensing Director

Insilico Medicine



Seda Larsen

Senior Director Global Alliance & Asset Management

Roche



Sonke Johanssen

Global Director, Advanced Therapies & Integrated Solutions Rare Disease

Novo Nordisk



Dr. Ulrich A.K. Betz

VP of Innovation, Chairman of the Board Future Insight

Merck



Xiaona Jing

SVP Global Product Development & Partnering at Multitude Therapeutics

Multitude Therapeutics



Ying Wang-Schmidt

Senior Director of Business Development

Roche

Conference Agenda

DAY 1

DAY 0 | 31 March 2025

18:00 PRE-EVENT MEET & GREET

Kick off the experience with some drinks while taking advantage of early bird registration and the chance to connect with fellow delegates. As everyone starts arriving, this is the perfect opportunity to network, catch up with familiar faces, and meet new ones. Raise a glass, spark conversations, exchange handshakes, share smiles, and embrace the camaraderie—whether reconnecting with old friends or forming new bonds in the industry, everyone is warmly welcomed here!

8:50 Chairperson's Opening Remark

Luis Correia, Founder & CEO, Basel Biotech Consulting

9:00

Fireside Chat: Decoding Investment Potential – An Investor's Perspective on What Drives Confidence in Early-Stage Biotech Companies

Join us for a captivating fireside chat as a seasoned investor pull back the curtain on what really drives their decisions. Discover how market dynamics, innovation potential, leadership quality, and strategic foresight intersect to determine which companies receive funding. With real-world anecdotes, insider insights, and a deep dive into market trends, this discussion will equip you with the tools to stand out to investors, transform risk into opportunity, and navigate the evolving biotech investment landscape. Don't miss this electrifying conversation—essential for anyone looking to understand and influence investment potential in this competitive sector!

Key discussion points:

- Key criteria investors use to assess the potential of early-stage biotech companies.
- How scientific innovation and market fit influence investment decisions.
- Why a strong leadership team and strategic vision are critical for building investor confidence
- Strategies for managing risk and addressing uncertainties to attract early-stage funding
- Real-world examples of successful biotech investments and lessons learned.

This fireside chat will equip biotech entrepreneurs and professionals with a clear understanding of what drives investment decisions, helping them build compelling cases for their ventures.

Rainer Strohmenger, Managing Partner, Wellington Partners

9:30

Panel Discussion: Identifying and Evaluating Potential Partners and External Pipeline: Building Strategic Collaborations

This panel discussion will focus on how pharma companies can identify and evaluate potential external partners and innovative pipelines to enhance their R&D efforts and accelerate time-to-market. Industry experts will discuss best practices for sourcing and assessing collaboration opportunities with biotech startups, academic institutions, and other partners. The session will also cover key considerations for conducting due diligence and structuring partnerships that maximize value for both parties.

Key discussion points:

- Sourcing external innovations and identifying promising partners.
- Criteria for evaluating strategic fit, including scientific and cultural alignment.
- Conducting due diligence: regulatory, financial, and technical assessments.
- Structuring partnerships: licensing, joint ventures, and strategic alliances.
- Leveraging technology to improve partner selection and portfolio management.
- Navigating big pharma's priorities, including scalability, innovation potential, and market fit.

This session will equip pharma executives with actionable insights to make informed decisions when seeking external partnerships, ensuring successful collaborations that drive growth and innovation.

Delphine Demeestere, Director of External Innovation, Lonza

Hiro Usuda, Scouting & Transaction Lead, Business Development, Astellas Pharma

Jean Eric Charoin, Search & Evaluation lead for CVM12, Roche

Ricardo Gaminha Pacheco, Strategic Partnering, Business Development & Licensing Director, Insilico Medicine

10:10

Panel Discussion: Deal Making in Pharma and Biotech – Perspectives from Big Pharma, Investors, and Innovation Leaders

This panel discussion will explore the critical dynamics of deal-making across biotech, big pharma, and the investor community. Esteemed experts from these sectors will share their perspectives on aligning strategic priorities, navigating diverse motivations, and fostering mutual understanding to drive successful partnerships. The session will highlight what big pharma and investors prioritize in collaborations and how biotech companies can position themselves to maximize their partnership opportunities.

Key discussion points include:

- Understanding the motivations and expectations of big pharma, investors, and biotech in strategic partnerships.
- Strategies for biotech firms to position their innovations to attract pharma and investor interest.
- Lessons learned and insights from real-world examples of complex deal-making.

Conference Agenda

DAY 1

This session aims to equip biotech leaders, pharma executives, and investors with practical strategies and insights to build value-driven, enduring partnerships.

Louise Jopling, *Chief Scientific & Innovation Officer, Babraham Research Campus*
Michael R Huebner, *Director, Country Lead Switzerland, Early Innovation Partnering, Johnson & Johnson*

Rainer Strohmenger, *Managing Partner, Wellington Partners*

Ying Wang-Schmidt, *Senior Director Business Development, Roche*

10:50 Coffee Break with Exhibit Viewing

11:20

Case Study: Creating Successful Deals and Partnerships: Exploring Value Drivers Across the BD Life Cycle

This session will delve into the essential value drivers that underpin successful deals and partnerships in the pharmaceutical industry. From early negotiations to long-term strategic alliances, our speaker will share his perspective on how companies can effectively identify, align, and leverage value drivers throughout the business development lifecycle. The session will provide attendees with actionable strategies to create mutually beneficial deals and ensure lasting success in today's competitive landscape. Join us for an engaging exchange of ideas that offers both industry insights and practical takeaways.

Key takeaways:

- Understanding value drivers at every stage of the BD life cycle.
- Approaches to negotiating and structuring high-value deals.
- Aligning partner goals and managing expectations for long-term collaboration.
- Mitigating risks and addressing uncertainties in partnerships.
- Leveraging data and digital tools to enhance deal-making processes.

This session will equip leaders with the insights and tools needed to navigate complex partnerships and create deals that deliver sustained value and innovation.

Lev Kogon, *VP & Head of Business Development, Nykode Therapeutics*

11:50

Case Study: Drug Asset Transition: The Forgotten Patient

This presentation aims to shed light on the often-overlooked aspect of asset transition—compassionate use programs. While much attention is given to clinical trials, supply chain processes, and deal negotiations, the ongoing patients benefiting from compassionate use can sometimes be forgotten. For assets in oncology, neurology, and rare diseases, this scenario occurs far more frequently than one might expect. Through a case study, we will explore the consequences of overlooking these patients during asset transitions.

Key Takeaways:

- Understanding how to identify CUP/EAP patients outside the clinical trials
- Discuss practical strategies to address and resolve these challenges once they are identified
- Strategies to align both companies to transition these patients
- Ensuring that no patient is forgotten in the transition process

Ana Paula Tediosi, *Head of Expanded Access Program Strategy, WEP Clinical*

12:20 Networking Lunch

13:20

Fireside Chat: AI in Pharma – From Hype to Reality

This session will examine the real-world applications of artificial intelligence (AI) in the pharmaceutical industry, moving beyond the hype to explore how AI is truly transforming drug discovery, clinical trials, and diagnostics. Experts will discuss the practical challenges and opportunities of integrating AI into pharma workflows, as well as the potential for AI to accelerate innovation and improve patient outcomes.

Key discussion points:

- Real-world examples of AI's impact on drug discovery and development.
- Data-driven decisions leveraging AI for adaptive clinical trial designs.
- AI in medical imaging: enhancing diagnostics and early detection of diseases.
- Addressing the challenges of data quality, regulatory hurdles, and ethical considerations.
- Balancing AI integration with traditional pharma processes for maximum effectiveness.

This session will provide pharma professionals with insights into how AI is moving from a buzzword to a powerful tool, enabling more efficient and accurate processes across the industry.

Ricardo Gaminha Pacheco, *Strategic Partnering, Business Development & Licensing Director, Insilico Medicine*

13:50

Keynote: Crowdsourcing and Open Innovation: Redefining Pharma's Approach to Discovery

In an era where collaboration fuels innovation, Merck is leading the charge in crowdsourcing and open innovation to solve pharma's toughest challenges. This keynote will explore how initiatives like the Innovation Cup, Future Insight Prize, and Compound Synthesis Challenge are transforming traditional boundaries and accelerating breakthroughs. Attendees will gain insights into Merck's strategic use of open innovation to drive impactful discoveries and shape the future of healthcare.

From Legacy to Movement: How Merck turned its 350th anniversary into a global innovation catalyst.

Conference Agenda

DAY 1

Key Takeaways:

- Merck Innovation Cup: Inspiring collaboration to address urgent healthcare challenges.
- Future Insight Prize – Visionary Science: Predicting global health threats through groundbreaking research awards.
- Merck Research Grants: Empowering scientists to tackle key pharma challenges.
- Curious – Future Insight Conference: Convening global minds to envision science's future.
- Compound Synthesis Challenge: Open innovation in action for complex chemical synthesis.

Dr. Ulrich A.K. Betz, VP of Innovation, Chairman of the Board Future Insight, Merck

14:20 Innovation Spotlight

Empowering Pharma Futures with Delta4: Our Strategy to Reclaim and Reinvent Your Drug Portfolio

Delta4's AI-driven Hyper-C platform leverages advanced data analytics to reclaim established compounds, broadening their indication space and unlocking innovative therapeutic combinations. This transformative strategy redefines drug discovery and accelerates the journey from research to enhanced patient care.

Kurt Herpel, CEO, Delta4

14:40 Coffee Break with Exhibit Viewing

15:10

Networking Exchange: Connect, Collaborate, Grow

This 90-minute session is dedicated to meaningful networking with industry peers—no panels, no presentations. Attendees can pre-arrange meetings via the networking app or engage in spontaneous discussions to build connections and explore collaborations in the pharma and biotech space.

16:40 Chairperson's Closing Remarks

16:45 End of Day One

8:50 Chairperson's Opening Remark

Isabella Visconti, Founder, **Visconti Alliance Management**

9:00

The Power of Partnerships: Driving Innovation Across Pharma's Value Chain – Commercial Case Study

While many focus on the early stages of drug development – preclinical, clinical trials, and market launch – true innovation continues to thrive throughout the commercial stage. This real-world commercial case study will illustrate how strategic alliances and partnerships, particularly in the commercialization phase, can drive sustained innovation, maximize market access, unlock synergies, and enhance long-term patient outcomes.

Key takeaways will include:

- The critical role of partnerships not just in early development but in driving continued innovation through commercialization.
- Overcoming challenges in scaling and expanding partnerships during the post-launch phase.
- Best practices for sustaining impactful partnerships that support ongoing product growth, market access, and patient engagement.
- Leveraging emerging technologies like AI and data analytics to enhance commercial strategies and drive new market opportunities.

Attendees will gain actionable insights into how to continue pushing the boundaries of innovation well beyond the launch stage, ensuring the long-term success of pharma-partnerships.

Benjamin Fischer, VP Global Alliance & Integration Management, **STADA Group**

9:30

Case Study: Mastering M&A: How Tillotts Became a Preferred Partner in European Specialty Pharma

Key Takeaways:

- Example of recent M&A project underlining Tillotts' strong track record in partnerships
- Partnering strategy covering entire spectrum from M&A transactions to marketing co-operations with tailor-made agreements
- Governance and decision making in multi-cultural environment ensuring quick execution of deals and integrating assets into product portfolio
- Tillotts' journey to become a truly European Specialty Pharma Company

Ragip Ziyal, Head of Corporate Development, **Tillotts Pharma**

10:00

Panel Discussion: The Pharma's View – Are Deals with Big Pharma Becoming Faster, More Collaborative, and More Creative or Just More Complicated?

This panel discussion will explore the evolving nature of deals between big pharma and its partners. Industry leaders will debate whether partnerships are becoming more efficient and innovative or if the increasing complexity of the industry is leading to slower and more challenging deal-making processes. The session will cover emerging trends in collaboration, creative deal structures, and the practical realities of navigating these partnerships in a competitive landscape.

Key discussion points:

- Are deals becoming faster and more efficient, or are there growing hurdles?
- How collaboration and creativity are influencing deal structures in pharma.
- The role of technology and data in facilitating or complicating partnerships.
- Navigating regulatory, legal, and cultural complexities in global deals.
- Case studies on innovative and successful deal-making processes.

This session will offer valuable insights for pharma professionals seeking to understand the current state of deal-making with big pharma and how to adapt to these changing dynamics.

Ragip Ziyal, Head of Corporate Development, **Tillotts Pharma**

Huseyin Ocak, Global Alliance Management Lead, Consumer Healthcare, **Opella**

Charlie Bailey, BD&L Transactions Head, Global Health, Corporate & Business Development, **Novartis AG**

10:30 Coffee Break with Exhibit Viewing

11:00

Case Study: Building an Innovation Ecosystem in Partnership with Academia, Biotech, Corporates and Investors

- Establishing a Thriving Life Sciences Hub – Driving collaboration by co-locating academia, biotech startups, established corporates, and investors to accelerate innovation.
- Creating the Ideal Environment for Growth – Providing world-class infrastructure, funding access, and expert support to help bioscience businesses launch, scale, and expand.
- Fostering a High-Impact Ecosystem – Enabling breakthrough discoveries, next-generation therapeutics, job creation, and economic growth to strengthen the UK's position in global life sciences.
- Real-World Impact: Success Stories from New Tenants – Showcasing three case studies of companies that have benefited from the campus ecosystem, demonstrating tangible innovation, collaboration, and growth.

Louise Jopling, Chief Scientific & Innovation Officer, **Babraham Research Campus**

11:30

Panel Discussion: Strategic Deal Execution – Overcoming Challenges and Maximizing Success

This panel will focus on how pharma companies can effectively execute deals and manage partnerships to ensure long-term success. Industry experts will share insights into the practical challenges that often arise post-deal and offer strategies for navigating these complexities. The session will highlight real-world examples of successful partnerships and how companies overcame obstacles to maintain alignment and value creation.

Key discussion points:

- Overcoming operational and regulatory challenges during collaborations.
- Best practices for negotiating and aligning interests to establish successful, long-term collaborations.
- Ensuring flexibility and adaptability in deal execution.
- Real-world examples of overcoming obstacles in partnerships.
- Strategies for managing conflicts and maintaining alignment between partners.
- Case studies of successful and challenging deals.

This session will provide attendees with actionable insights on how to manage partnerships effectively and navigate the complexities of executing deals in the pharmaceutical industry.

Fadi Eskandar, SVP, Head Of External Ecosystem Collaboration And Partnership, Innovative Assets, **Dr. Reddy's Laboratories**

Jari Kaunisto, Business Development Director, **Orion Corporation**

Seda Larsen, Senior Director Global Alliance & Asset Management, **Roche**

Benjamin Fischer, VP Global Alliance & Integration Management, **STADA Group**

12:10 Networking Lunch

13:10

Fireside Chat: Thinking Beyond the Molecule – How Large Pharma Companies Leverage External Partnerships

This fireside chat will explore how leading pharmaceutical companies are expanding their offerings beyond the core molecule through strategic external partnerships. It will examine how these partnerships enhance value, enable access to complementary technologies, and accelerate innovation across the healthcare ecosystem. The fireside chat will also highlight real-world examples of how large pharma companies are working with external partners to create comprehensive solutions that address unmet needs in patient care.

Key learning points:

- How pharma companies are thinking beyond traditional drug development to deliver broader healthcare solutions.

- Leveraging external partnerships to access new technologies, expertise, and market opportunities.
- Case studies of successful partnerships that have created value beyond the molecule.
- Strategies for identifying the right partners and structuring effective collaborations.
- Lessons learned from navigating challenges in external partnerships.

This fireside chat will provide valuable insights into how large pharma can extend their impact through strategic partnerships, delivering innovative solutions that go beyond the molecule.

Moderator: Alberto Mussa, Head of Strategy, Business Development & Alliances, **Sanofi**

Speaker: Sonke Johanssen, Global Director, Advanced Therapies & Integrated Solutions Rare Disease, **Novo Nordisk**

13:40

Keynote: Transformation Innovation Journey

- Expanding patient access to innovative medicines through strategic partnerships
- An innovation ecosystem to accelerate medicine development
- The real art of building a Consumer Health business

Fadi Eskandar, SVP, Head of External Ecosystem Collaboration and Partnership, Innovative Assets, **Dr. Reddy's Laboratories**

14:10 Innovation Spotlight 1

Contribution of The Contract Laboratory Organization to Regulatory Submissions

Gabriela M. Visser, Founder & CEO, **Q-PRO Laboratories**

14:30 Innovation Spotlight 2

ADC Innovation in Challenging Solid Tumors: Insights from MabArray Target Discovery and T-Moiety–Exatecan Synergy

Multitude Therapeutics is a clinical-stage biotech company utilizing its proprietary target and antibody discovery platform, Human Membrane Proteome MabArray™, in combination with its T1000 ADC platform, to develop innovative cancer therapeutics. The company's clinical pipeline features potential first-in-class and best-in-class antibody-drug conjugates (ADCs) aimed at treating solid tumors with high unmet medical needs. Additionally, two of its preclinical assets have been successfully licensed to partners in the U.S. and Europe.

Xiaona Jing, SVP Global Product Development & Partnering at Multitude Therapeutics, **Multitude Therapeutics**

14:50 Coffee Break with Exhibit Viewing

Conference Agenda

DAY 2

15:20

Networking Exchange: Connect, Collaborate, Grow

This 90-minute session is dedicated to meaningful networking with industry peers—no panels, no presentations. Attendees can pre-arrange meetings via the networking app or engage in spontaneous discussions to build connections and explore collaborations in the pharma and biotech space.

16:50 Chairperson's Closing Remarks

16:55 End of Conference

2025 PPM Summits **Worldwide**



- 1** 22 – 23 January, BARCELONA
28th European Pharma and Biotech Project, Program and Portfolio Management Conference
- 2** 29 – 30 January, SAN DIEGO
American Strategic Portfolio Management in Life Sciences – West Coast
- 3** 3 – 4 April, BASEL
29th European Biopharma Project Program and Portfolio Management Conference
- 4** 9 – 10 April, CHICAGO
2nd American Medical Device Project & Portfolio Management Conference
- 5** 15 – 16 April, PHILADELPHIA
24th American Pharma and Biotech Project, Program and Portfolio Management Conference
- 6** 14 – 15 May, LONDON
European Strategic Portfolio Management in Life Sciences
- 7** 3 – 4 June, COPENHAGEN
Biopharma PPM in Clinical Research and Development Summit Edition
- 8** 11 – 12 June, BERLIN
2nd European MedTech Summit 2025 – Medical Device Project & Portfolio Management Conference
- 9** 11 – 12 June, SAN FRANCISCO
25th American Pharma and Biotech Project, Program and Portfolio Management Conference
- 10** 5 – 6 August, SINGAPORE
Asian Pharma and Biotech Project, Program and Portfolio Management Conference
- 11** 3 – 4 September, MELBOURNE
Pharma and Biotech Project, Program and Portfolio Management Conference
- 12** 10 – 11 September, MUMBAI
3rd Strategic Project, Program and Portfolio Management Conference for Pharmaceuticals
- 13** 8 – 9 October, BASEL
30th European Pharma and Biotech Project, Program and Portfolio Management Conference
- 14** 15 – 17 October, BOSTON
26th American Pharma and Biotech Project, Program and Portfolio Management Conference
- 15** 22 – 23 October, LONDON
31st European Pharma and Biotech Project, Program and Portfolio Management Conference
- 16** 9 – 11 December, LAS VEGAS
2nd Annual PPM TOOLBOX SUMMIT

Our Partners



Contact us

Updated: 28 March, 2025
for the latest programme update, please
download agenda on conference website



Attending:



Liza Zhaivoronok

Vice President, PPM World Tour
liza.zhaivoronok@whysummits.com

Speaking:



Jenn See

jenn.see@whysummits.com

Sponsoring:



Srihari Kamban

shk@whysummits.com

Disclaimer:

Please note - all of the information in this document is subject to change at any time. Whilst every effort has been made to ensure the accuracy of the information, statements and decisions recorded in them, their status will remain that of a draft until such time as they are confirmed as a final version prior the subsequent meeting. Additionally, the user information is only valid at a certain moment in time and is subject to change due to movement and changes in bit rate requirements.

"Always be Curious"

www.whysummits.com

REGISTER HERE



€2399